Recombinant DNA technology (rDNA) helps to identify the gene function and its regulation in normal and pathogenic condition. Recombinant DNA is created artificially from two or more DNA molecules, which are incorporated into a single molecule. Recombinant DNA technology examines the functioning of the living system by manipulating their genome for production of useful metabolites. Recombinant DNA technology has introduced new classes of organism namely genetically modified organism (GMO) or living modified organism (LMO). It can develop genetically modified crops (BT cotton), cloned animals, bio pesticides, biofuel, bioremediation, and gene therapy successfully. Impact of rDNA on human and environment in the context of safety is assessed by researchers.
Advance rDNA technology have resulted in production of various therapeutic proteins, such as insulin, hormones, edible vaccines, interleukins, and monoclonal antibodies. It has enormous potential to revolutionize the medical and clinical medicines. rDNA technology has triggered the biopharmaceutical industries towards the development of various rDNA product, in turn favoring the growth of recombinant DNA technology market.
Request For Sample [email protected]
Global recombinant DNA technology market – trends and opportunity
At Jef Boeke’s lab, 2017, scientists are rewriting the yeast genome, which aims to create custom-made chunks of DNA codes, which can be inserted into the cells to alter their functions and improve drug development. Researchers intend to construct whole new organisms with functional genes, which will help to develop vaccines, proteins, drugs, and biofuels.
According to Applied Science Report, 2013, integrating biotechnology and genomics in the drug development process gives the opportunity to companies to save up to US$ 300 million per drug, which is about one-third of the cost of the drug. This prospect is bringing drug two year earlier in the market, indicating the significance of recombinant drugs and the need for manufacturing.
Increasing investments in research and development pool to favor the growth of recombinant DNA technology
Increasing government funding in the U.S. by the Department of Health And Human Services (HHS) to National Institute of Health’s research and development for various disciplinary field gene therapy applications is the major driving factor for the growth of recombinant DNA technology market. Effect of various factors, such as food, health problems, and environmental issues on growing population is another driving factor for the growth of recombinant DNA technology market. Diseases such as cancers, genetic disorder, plant and animal disorders, and development of anti-fungal or anti-viral abilities of plants have high demand in therapeutic approaches, which will favor the growth of recombinant DNA technology market.
Lack of government funding for research and development in emerging economies is the major restraint for the growth of recombinant DNA technology market.
The major key players operating the recombinant DNA technology market include Horizon Discovery Group PLC, F. Hoffmann-La Roche Ltd (Genentech, Inc), Profacgen, Cibus; Monsanto Company, Amgen Inc., New England Biolabs, Novartis AG, GenScript, GlaxoSmithKline plc, Pfizer Inc., Novo Nordisk, and Eli Lilly and Company.
Ask For customization: